title: Tacrolimus (FK506) proves superior to OKT3 for treating episodes of persistent rejection following intrathoracic transplantation.
authors.affiliation: Department of Cardiac Surgery, University of Munich, Grosshadern Medical Center, Germany.
authors.forename: B M
authors.initials: BM
authors.lastname: Meiser
authors.forename: P
authors.initials: P
authors.lastname: Uberfuhr
authors.forename: C
authors.initials: C
authors.lastname: Schulze
authors.forename: A
authors.initials: A
authors.lastname: Fuchs
authors.forename: H
authors.initials: H
authors.lastname: Mair
authors.forename: H
authors.initials: H
authors.lastname: Reichenspurner
authors.forename: E
authors.initials: E
authors.lastname: Kreuzer
authors.forename: B
authors.initials: B
authors.lastname: Reichart
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000188:drug therapy*; D016027:Heart Transplantation / Q000276:immunology* / Q000379:methods; D016041:Heart-Lung Transplantation / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016040:Lung Transplantation / Q000276:immunology*; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016559:Tacrolimus; D008775:Methylprednisolone; D008727:Methotrexate